Taking the drug anastrozole for five years may reduce the chances of post-menopausal women at high risk of breast cancer developing the disease, new research has found.
The study of more than 3,800 women with breast cancer found that the drug reduced the risk of developing breast cancer by 53% compared with women who took a placebo.
The researchers say it offers an alternative to tamoxifen which has more side effects and is less effective.
The study was partially funded by AstraZeneca, which manufactures anastrozole and tamofixen.
Read more at The University of Western Australia